The FDA has restored GHK-Cu for non-injectable use to Category 1 of its 503A bulk drug substances list, reversing an April 22, 2026 removal that compounding pharmacies had been scrambling to interpret for the better part of a month
Saraceni B
And if you're working with leafy greens or herbs, a salad spinner with a good rinse goes a long way
A., Kukarni K., Cergol K
Prepare for your consultation by: Documenting your current rheumatoid arthritis symptoms, disease activity, and treatment history Listing all current medications, including DMARDs, biologics, corticosteroids, and analgesics Noting any comorbidities, particularly diabetes, obesity, cardiovascular disease, or gastrointestinal conditions Being honest about your treatment goals and what has prompted interest in GLP-1 therapy Questions to discuss with your doctor : What is the current evidence for GLP-1 use in rheumatoid arthritis
Also, 31.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 15.3% for semaglutide 2.4 mg and 0.0% for placebo
